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Regulation of protein synthesis, although known for many decades, has only recently begun to be recognized as a critical control 
mechanism for the maintenance of cellular homeostasis and cellular stress response. One of the key advantages of translational control 
is the ability of cells to rapidly reprogram the protein output in response to internal or external triggers. This is particularly important 
during cellular response to stress that may lead to apoptosis by providing cells with a fine tuning mechanism that tips the balance between 
cell survival or apoptosis. In the following review we highlight several distinct mechanisms of translation control and provide specific 
examples of translational control during apoptosis. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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MECHANISMS OF TRANSLATION 
INITIATION
The regulation of gene expression occurs at many 
levels including the transcriptional and translational 
steps. In order for a cell to quickly respond to its 
changing environment, control of gene expression 
at the translational level is ideal since it allows for 
rapid and immediate changes in protein levels required 
to respond to the particular stress. Protein translation 
can be separated into three main steps including initia-
tion, elongation, and termination. Translation initiation 
is often regarded as the rate-limiting step and thus 
it is highly regulated by several mechanisms including 
modifications of the initiation factors involved in the 
process as well as regulation by microRNAs.
The principal method of translation initiation occurs 
by means of a cap-dependent scanning mode, which 
is the primary source of de novo synthesized cellular 
proteins under normal growth conditions (Fig. 1). 
This process requires the involvement of many 
eukaryotic initiation factors (eIFs), which themselves 
can be regulated to control rates of protein synthesis, 
as will be discussed below. In brief, the cap-dependent 
process involves the recognition of the 5’ m7G cap 
structure, invariably present on all mature cellular 
messenger RNAs (mRNAs), by the eIF4F complex, 
comprised of the cap binding protein eIF4E, the scaf-
fold protein eIF4G, and the RNA helicase eIF4A. Sepa-
rately, the formation of the 43S pre-initiation complex 
occurs through the association of the 40S ribosomal 
subunit with eIF3, eIF1A, and eIF2 bound to the initia-
tor methionyl transfer RNA (Met-tRNA; Met). The 43S 
pre-initiation complex is then recruited to the mRNA 
through the interaction between eIF3 and eIF4G and 
is believed to subsequently scan the mRNA until 
it locates the initiation codon, typically AUG, in an ap-
propriate context. Subsequently, joining of the 60S 
ribosomal subunit occurs, which forms the transla-
tionally competent 80S ribosome, while the eIFs are 
released and recycled for the next round of initiation. 
Furthermore, poly(A)-binding protein (PABP) associ-
ates with the poly(A) tail on the 3’ terminus of mRNA 
and is thought to interact with eIF4G causing circu-
larization of the mRNA to enhance translation as well 
as to protect the mRNA from degradation (see Fig. 
1 for details, reviewed in [1]). 
The process of translation consumes a significant 
amount of cellular energy (estimated to be as much 
as 50%, depending on the organism [2]). It is there-
fore not surprising that exposure of cells to majority 
of environmental stressors such as hypoxia, irradia-
tion, or nutrient deprivation leads to modifications 
of the eIFs involved in the regulation of cap-dependent 
translation, ultimately resulting in attenuation of global 
protein synthesis. In addition to saving cellular en-
ergy, the attenuation of translation prevents synthesis 
of unwanted proteins that could obstruct the cellular 
stress response. Under these conditions, cells are able 
to cope with the stress or, if the damage to the cell 
is beyond repair, to initiate apoptosis. To facilitate the 
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Fig. 1. Schematic diagram outlining the key points of regulation during translation initiation. For simplicity, not all initiation 
factors are shown. Initiation factors that are described in this review are indicated with asterisks. (Adapted from [123])
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decision making process, some proteins, in particular 
those required for the stress response, are selectively 
translated even though cap-dependent translation 
is attenuated. It is the relative levels of these pro- and 
anti-apoptotic proteins that are important in tipping the 
balance in favour of survival or cell death. The ques-
tion of how a cell is able to translate proteins when 
the required eIFs for cap-dependent translation are 
not available is at the centre of investigations in many 
laboratories, and a subject of this review. 
One important mechanism that has acquired recent 
attention is the internal ribosome entry site (IRES) 
mediated translation initiation process that utilizes 
specialized RNA elements to selectively recruit ribo-
somes to mRNA without a need for the cap structure 
[3]. IRES elements are found in the 5’ untranslated 
region (UTR) of mRNAs and were initially discovered 
in RNAs of picornaviruses [4]. Although the RNAs 
of these viruses do not contain a m7G cap, they are 
still effectively translated. In addition, many viruses 
encode proteases that cleave several canonical eIFs 
in order to block translation of host proteins. For 
example, upon infection of cells with polio virus, the 
virus-encoded protease 2A specifically cleaves eIF4G 
thus inactivating the eIF4F complex and effectively 
preventing ribosome recruitment to capped cellular 
mRNAs. This ensures that the host cell’s translational 
machinery is now available for virus protein translation 
[5]. Importantly, the polio virus IRES element is able 
to utilize the cleaved eIF4F complex and recruit the 
ribosome for efficient translation of its own proteins. 
In other viruses, such as the hepatitis C virus (HCV), 
the presence of eIF4F is not required at all and the IRES 
is able to recruit the ribosome in its absence [6]. Thus, 
even with the loss of some eIFs, the viral IRES elements 
are able to recruit the ribosome for efficient translation. 
These observations led researchers to study cellular 
mRNAs to determine if a similar mechanism(s) exists. 
In recent years, it has been proposed that an estimated 
10% of all cellular mRNAs may contain IRES elements. 
Interestingly, many of these mRNAs encode proteins 
involved in processes such as cell proliferation and 
apoptosis, and are critical in determining the survival 
of a cell under physiological and pathophysiological 
stress conditions [3]. For example, IRESs have been 
identified in mRNAs encoding XIAP, cIAP1, Bcl-xL, Bcl-
2, Bag-1, Apaf-1, p53, c-myc, DAP5, all proteins that 
are critically involved in the regulation of cell survival.
Although the mechanism of IRES-mediated transla-
tion is still poorly understood, it has become evident 
that not all cellular IRES elements act in a similar man-
ner. That is, most cellular IRES elements require bind-
ing of some of the canonical initiation factors as well 
as for other protein factors termed ITAFs (IRES-trans 
acting factors) that modulate the IRES activity [3]. Most 
of the ITAFs identified thus far are RNA binding proteins 
that fulfill a variety of functions including involvement 
in mRNA splicing (for a review on splicing in apopto-
sis see [7]), export, stress granule formation, as well 
as having important roles in translation initiation. The 
binding of ITAFs can either enhance or repress IRES 
activity; it is thought that the positive regulators act 
either as RNA chaperons that aid in the formation of the 
proper IRES structure, or directly recruit the ribosome. 
The precise mechanism of how the repressive ITAFs 
function is not clear. Interestingly, many ITAFs shuttle 
between the nucleus and cytoplasm and this shuttling 
is regulated by posttranslational modifications such 
as phosphorylation in response to a variety of trig-
gers. Therefore, the cytoplasmic availability of posi-
tive or negative regulators can determine the extent 
of IRES translation (see below).
Table. Select eukaryotic translation initiation factors that are modified during apoptosis induced by different triggers. The type of modifica-
tions and their consequence for translation and cell survival, along with key references are shown on the right
Translation ini-
tiation factors Modifications Effects Apoptotic triggers References
eIF2 Phosphorylation of eIF2α subunit 
at Ser51
Inhibition of GDP to GTP exchange on eIF2:
•	inhibition of global translation and apoptosis
•	translation of specific transcripts and cell survival
Iron deficiency, heavy metals, osmotic 
or oxidative stress, heat shock, dou-
ble stranded RNA, amino acid starva-
tion, unfolded protein response (UPR)
[1, 11]
eIF4E De-phosphorylation Global translation inhibition. Stimuli that activate protein phos-
phatase 2A
[20]
4E-BPs De-phosphorylation Competition with eIF4G on eIF4E. Global transla-
tion inhibition and apoptosis
DNA damage, TRAIL, staurosporine, 
rapamycin
[12, 16, 21, 
22]
4E-BPs Cleavage by caspases at Asp-24 Cleaved form strongly binding eIF4E and inhibi-
tion of cap-dependent translation
Staurosporine, etoposide, p53 ac-
tivation
[21, 22]
eIF4GI and eI-
F4GII
Cleavage by caspase 3 at Asp-
532 and Asp-1176 of eIF4GI. 
Cleavage by caspase 3 at Asp-560, 
851, 978, 1162 and 1407 of eIF4GII.
Cleaved forms (except for M-FAG from eIF4GI) 
cannot bridge eIF4E, 4A and eIF3 together. Glo-
bal translation and attenuation of anti-apopto-
tic response
TNFα, TRAIL, cisplatin, etoposide, 
cycloheximide, MG132, serum de-
privation, Fas receptor activation
[3, 9, 16]
p97/DAP5/
NAT1
Cleavage by caspase 3 at Asp-790 p86 fragment with eIF4A and eIF3 binding sites 
but no eIF4E site. Inhibition of cap-dependent 
translation but stimulation of specific IRES-de-
pendent translation
UPR, Fas receptor activation [18, 26–28]
eIF4B Cleavage by caspase 3 at Asp-45 Fragment is still able to interact with eIF4F and 
eIF3 but lacks the region mediating PABP binding
Cycloheximide, Fas receptor acti-
vation
[16, 31–33]
eIF3j (p35) Cleavage by caspase 3 at Asp-242 Reduced affinity of the eIF3 complex for the 40S ribo-
somal subunit. Inhibition of global protein translation
Cycloheximide, Fas receptor acti-
vation
[16, 29]
eIF3f (p47) Phosphorylation Enhanced association with the core subunits 
of eIF3. Inhibition of global protein translation
Staurosporine [30]
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GLOBAL TRANSLATION REGULATION 
DURING APOPTOSIS: MODIFICATIONS 
OF TRANSLATION INITIATION FACTORS 
Induction of apoptosis is accompanied by a pro-
nounced down-regulation of protein synthesis [8]. 
This inhibition in global translation rates is character-
ized by a decrease in polysome chains, suggesting 
that at least some regulation occurs at the translation 
initiation step [9]. Indeed, there is extensive evidence 
that apoptosis triggered by different stimuli leads 
to modifications in a defined set of canonical initiation 
factors that ultimately results in the inhibition of trans-
lation initiation (reviewed in [8, 10]). These modifica-
tions generally consist of changes in phosphorylation 
status (e.g. eIF2α, eIF4E, eIF3, eIF4E binding proteins 
(4E-BPs)) or protein cleavage by caspases or viral 
proteases (e.g. eIF4G, eIF4B, eIF3 (Table; Fig. 2)). 
eIF2α
eIF2 plays a central role in translation initiation 
by bringing the initiator Met-tRNA to the 40S ribosomal 
subunit for the formation of the 43S pre-initiation com-
plex. eIF2 is composed of three subunits (α, β and γ), 
of which the γ subunit is bound by GTP that is later 
hydrolyzed during translation initiation [1]. GDP to GTP 
exchange is necessary for regenerating active eIF2 and 
this process is catalyzed by eIF2B (Fig. 1). However, 
in response to different stress stimuli, the α subunit 
of eIF2 is phosphorylated at serine 51 (Ser51), thus 
increasing its affinity for eIF2B and trapping the two 
in an inactive complex [11]. As a result, pre-initiation 
complex formation and global mRNA translation are 
inhibited. eIF2α phosphorylation is mediated by four 
different kinases that are activated by various stress 
triggers (reviewed in [1]): HRI (haem-regulated in-
hibitor) which is activated by iron deficiency, heavy 
metals, osmotic or oxidative stress and heat shock; 
PKR (protein kinase activated by double-stranded 
RNA) which is activated by double stranded RNA 
from viral infections or interferon-induced apoptosis; 
GCN2 (general control non-derepressible-2) which 
is activated by amino acid starvation; and PERK (PKR-
like endoplasmic reticulum kinase) which is activated 
during the unfolded protein response (UPR). 
The link between eIF2α phosphorylation and apop-
tosis is not straightforward, and eIF2α phosphorylation 
can either be a cause or consequence of the cell’s com-
mitment to apoptosis. For instance, in MCF-7 breast 
cancer cells treated with TNFα or TRAIL (TNFα-related 
apoptosis-inducing ligand), eIF2α phosphorylation 
by PKR is dependent on caspase 8 [12, 13]. In contrast, 
in mouse embryonic fibroblasts treated with TNFα 
or deprived of serum, eIF2α phosphorylation is nec-
essary to induce caspase 3 activation [14]. Interest-
ingly, forced expression of a phosphomimetic S51D 
mutant of eIF2α is sufficient to activate caspase 3 and 
induce apoptosis in the absence of any other triggers, 
whereas expression of a non-phosphorylatable S51A 
mutant protects cells from TNFα or serum depriva-
Fig. 2. A model of the interconnectedness of translation and apoptosis. Only factors pertinent to this review are 
shown. The left side of the model shows regulation of cap-dependent translation; the right side depicts IRES-mediated 
translation. Green lines indicate positive, while red lines negative interactions. Dotted lines depicts indirect effect 
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tion. It has also been reported that eIF2α itself can 
be cleaved in apoptotic cells, mainly by caspase 3, but 
also by caspases 6, 8 and 10 [15, 16]. The functional 
relevance of this cleavage product is not fully under-
stood but it has been shown that its GTP exchange 
rate is higher, independent of eIF2B, and that it may 
contribute to translation inhibition [15].
In contrast to inhibiting global translation, eIF2α 
phosphorylation can up- or downregulate selective 
translation. For example, under hypertonic stress, 
eIF2α phosphorylation was shown to induce cytoplas-
mic accumulation of heterogeneous nuclear ribonu-
cleoprotein A1 (hnRNP A1), a known ITAF, which in turn 
inhibited IRES-mediated translation of the anti-apop-
totic proteins XIAP and Bcl-xL, thus sensitizing the cells 
to apoptosis [17]. Interestingly, in the context of the 
adaptive UPR, eIF2α phosphorylation can be a signal 
that promotes cell survival rather than apoptosis. In this 
context, eIF2α phosphorylation by PERK leads to the 
selective translation of transcription factors, such 
as ATF4 that controls the expression of pro-survival 
and anti-apoptotic proteins such as cIAP1 [3, 18]. 
eIF4E
The cap-binding protein eIF4E is another initiation 
factor whose availability is regulated by phosphory-
lation during apoptosis. eIF4E is phosphorylated 
at Ser209 by the MAPK integrating kinases Mnk1 and 
Mnk2 in response to different stimuli such as treat-
ment of cells with growth factors, anisomycin or UV, 
that activate the ERK and p38 MAPK pathways [19]. 
eIF4E phosphorylation reduces its affinity for the 5’ cap 
structure, thus stimulating translation initiation. Con-
versely, eIF4E dephosphorylation by protein phospha-
tase A leads to inhibition of global translation. However, 
eIF4E binding to the 5’cap is regulated mainly through 
the phosphorylation status of eIF4E binding proteins 
(4E-BPs). 4E-BP1, 2, and 3 are proteins that share 
structural similarities to the fragment of eIF4G respon-
sible for binding to eIF4E. 4E-BPs are phosphorylated 
in normal growth conditions by the mTOR signaling 
pathway (reviewed in [20]). However, during apoptosis 
induced by DNA damage, TRAIL, the protein kinase 
inhibitor staurosporine, or the mTOR inhibitor rapamy-
cin, there is a decrease in 4E-BPs phosphorylation 
[12, 16, 21, 22]. Hypo-phosphorylated 4E-BPs have 
a higher affinity for eIF4E and as a consequence, they 
competitively prevent eIF4G from binding to eIF4E, 
thus reducing the availability of the eIF4F complex 
and resulting in inhibition of translation (reviewed in 
[1]). Similar to eIF2α phosphorylation, loss of 4E-BPs 
phosphorylation occurs during the early phase of the 
apoptosis cascade [12, 16], leading to global transla-
tion inhibition and commitment to cell death. For ex-
ample, ectopic expression of a non-phosphorylatable 
mutant of 4E-BP1 sensitizes multiple myeloma cells 
to dexamethasone-induced apoptosis [23]. Fur-
thermore, apoptotic triggers such as staurosporine, 
etoposide or activation of p53 can lead to caspase-
mediated cleavage of 4E-BP1 [21, 22], producing 
a cleaved form that binds strongly to eIF4E and inhibits 
cap-dependent translation [24]. 
eIF4G
The availability and function of the initiation fac-
tors eIF4GI and eIF4GII is regulated during apoptosis 
primarily through cleavage by caspases. Upon treat-
ment of cells with apoptotic triggers such as TNFα, 
TRAIL, cisplatin or etoposide, eIF4GI and eIF4GII are 
cleaved by caspase-3 at two different sites. This gives 
rise to three cleavage products named Fragments 
of Apoptotic cleavage of eIF4G (N-FAG, M-FAG and C-
FAG [9, 16, 25]). The middle fragment, M-FAG, retains 
its ability to interact with eIF4A, eIF4E and eIF3, and 
supports cap-dependent translation during the early 
phase of apoptosis. However, M-FAG is degraded with 
prolonged exposure to stress resulting in the inhibition 
of cap-dependent translation and attenuation of the 
anti-apoptotic response. Interestingly, cleavage of the 
eIF4G-related protein factor p97/DAP5/NAT1 by cas-
pases releases a p86 isoform that stimulates the 
IRES-mediated translation of apoptosis regulating 
factors such as XIAP, cIAP1, c-myc, APAF1 and p97/
DAP5 itself [18, 26–28]. Hence, cleavage of eIF4G and 
p97/DAP5 proteins regulates the fate of the cell by tip-
ping the balance between the translation of pro- and 
anti-apoptotic factors. 
eIF3
eIF3 is a critical factor that bridges the bind-
ing between the 43S ribosome and eIF4F-bound 
mRNA. It has been reported that eIF3j (p35) is cleaved 
during apoptosis in BJAB cells treated with anti-Fas 
or cycloheximide [16]. eIF3j cleavage occurs in a cas-
pase-3 dependent manner and results in reduced 
affinity of the eIF3 complex for the 40S ribosomal 
subunit and subsequent inhibition of global translation 
[29]. Similarly, the p47 subunit of eIF3, eIF3f, is phos-
phorylated by CDK11 during staurosporine-induced 
apoptosis of the human melanoma cell line A376. eIF3f 
phosphorylation results in its enhanced association 
with the core subunits of eIF3 and sequestration in in-
soluble complexes, leading to an inhibition of protein 
synthesis and induction of apoptosis [30]. 
eIF4B
The initiation co-factor eIF4B which stimulates 
eIF4A helicase activity and ribosome binding to the 
mRNA, is also modified during apoptosis. eIF4B 
is cleaved in its C-terminal region by caspase 3 both 
in vitro and in BJAB cells treated with anti-Fas or cy-
cloheximide [16]. However, eIF4B can also be cleaved 
in a caspase-3 independent manner in apoptotic 
MCF-7 cells that lack caspase 3 [12]. The N-terminal 
fragment of eIF4B is still able to interact with eIF4F 
and eIF3 [16]; however, it lacks the region that me-
diates its interaction with PABP [31]. The effects 
of eIF4B truncation on translation and apoptosis are 
not well characterized. However, a substantial amount 
of work has been done on elucidating eIF4B’s role 
in cell survival and proliferation (reviewed in [32]). 
For instance, eIF4B depletion from HeLa cells using 
RNA interference was shown to selectively reduce the 
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translation of genes involved in cell proliferation (such 
as cdc25C, c-myc, and ornithine decarboxylase) and 
survival (such as Bcl-2 and XIAP). Moreover, eIF4B 
depletion caused a decrease in HeLa cells proliferation 
rates, enhanced apoptosis and sensitized these cells 
to camptothecin-induced cell death [33].
In general, modifications of translation initiation 
factors, whether they are a cause or a consequence 
of the initiation of the apoptotic cascade, are aimed 
at inhibiting global protein synthesis. This general in-
hibition of translation contributes to the shutdown of all 
cellular processes, and is believed to conserve cellular 
energy and prevent the synthesis of protein factors that 
could stall the apoptotic process. However, in cases 
of adaptive stress, translation can be reprogrammed 
such that the translation of specific mRNA transcripts 
continues and influences the fate of the cell (Fig. 2). 
SELECTIVE TRANSLATION VIA IRES
Despite the cessation of global protein synthesis 
during the early phase of apoptosis, selective trans-
lation of specific mRNAs can continue via the IRES 
mechanism, as described above. Several key regula-
tors of cell death were shown to be translated via IRES 
elements; here we focus on the regulation of transla-
tion of cIAP1, XIAP and p53.
Cellular inhibitor of apoptosis 1 (cIAP1) 
The inhibitor of apoptosis (IAP) family of proteins 
is comprised of eight members in mammals that regu-
late many key cellular processes including signaling, 
cell division, and apoptosis, and are the subject of an-
other review in this special issue [34]. cIAP1 is a key 
regulator of nuclear factor-κB (NF-κB) dependent 
signaling and capase-8 mediated cell death in mam-
malian cells. The abundance of cIAP1 in the cell 
is regulated at multiple levels: at the transcriptional 
level by the transcription factor NF-κB [35], at the 
protein stability level by autoubiquitination [36], and 
at the mRNA stability level by an AU-rich element 
(ARE) in its 3’UTR [37]. Importantly, cIAP1 expression 
in response to apoptotic triggers is mainly regulated 
at the level of protein translation. The cIAP1 mRNA 
has a long (1.2 kb) and highly structured 5’UTR that 
contains 23 AUG codons and two upstream open 
reading frames (uORF) which contribute to inhibition 
of its basal translation. In fact, the upstream ORF was 
shown to severely inhibit translation of the downstream 
ORF, thus explaining the low levels of cIAP1 observed 
under normal growth conditions [38]. Several stud-
ies have now established that cIAP1 expression 
is selectively upregulated in response to apoptotic 
stress [18, 39–41]. Indeed, cIAP1 protein expression 
is upregulated via an IRES-dependent mechanism 
in response to tunicamycin- or thapsigargin-induced 
endoplasmic reticulum (ER) stress, in conditions 
where global protein synthesis is inhibited [18, 42]. 
The relevance of cIAP1 IRES-mediated translation 
to ER stress induced apoptosis was further shown 
by the fact that cIAP1 overexpression attenuated 
tunicamycin-induced death in HeLa cells, whereas 
cIAP1 depletion by RNA interference enhanced sen-
sitivity to tunicamycin [18]. The importance of an IRES 
that drives cIAP1 expression to inhibit apoptosis was 
also demonstrated in the context of etoposide or so-
dium arsenite treatment [39] and viral infection [41].
Interestingly, activation of the cIAP1 IRES in the 
context of ER stress is dependent on caspase ac-
tivation and is accompanied by cleavage of eIF4GI 
and its homolog p97/DAP5/NAT1 during the early 
phase of the UPR [18]. As mentioned above, the p97/
DAP5/NAT1 cleavage product, p86/DAP5 functions 
as an ITAF that stimulates the activity of several IRES 
elements including cIAP1 [18, 26–28]. Indeed, ectopic 
overexpression of a p86/DAP5 fragment, but not the 
full length p97/DAP5 protein, in both HEK293T and 
rabbit reticulocyte lysates was able to specifically drive 
cIAP1 IRES acti vity and increase cIAP1 endogenous 
protein levels [18]. It was later shown that both p97/
DAP5/NAT1 and p86/DAP5 bind to the cIAP1 IRES, 
possibly through association with other accessory 
proteins [18, 42]. 
The structure of the cIAP1 IRES and the proteins 
that specifically interact with this IRES were character-
ized recently. One of these proteins, NF45, enhances 
cIAP1 IRES-dependent translation and mediates 
cIAP1 induction in response to thapsigargin-induced 
ER stress and UPR [40]. NF45 is an NFAT-related 
transcription factor that was first identified to regulate 
interleukin-2 transcription, together with its bind-
ing partner NF90 [43]. NF45 and NF90 are involved 
in several cellular processes such as transcription 
[44], viral replication [45] and microRNA processing 
[46] and our study confirmed its role in IRES-mediated 
translation [40]. More recently, NF45 has been impli-
cated in mitotic control in HeLa cells since depletion 
of NF45/NF90 complexes by RNA interference in these 
cells leads to the generation of large multinucleated 
cells, a result of impaired cytokinesis and cell growth 
due to defects in DNA break repair [47]. In line with 
this new role for NF45, we have recently discovered 
that NF45 preferentially regulates a cohort of AU-rich 
IRES-containing mRNAs including cIAP1 and XIAP, 
which are responsible for the multinucleated pheno-
type of NF45-deficient cells (MDF and MH unpub-
lished observations). Loss of NF45 results in reduced 
IRES-mediated translation of XIAP and cIAP1 mRNAs. 
Interestingly, the resulting decrease in XIAP expres-
sion causes an increase in Survivin protein levels, 
likely due to Survivin protein stabilization [48]. Survivin, 
another member of the IAP family, plays an important 
role in microtubule spindle checkpoint regulation and 
its aberrant expression leads to cytokinesis defects 
[49], thus explaining the multinucleated phenotype 
of NF45-deficient cells. Similarly, through its control 
of cIAP1 translation NF45 regulates cyclin E expres-
sion. Nuclear cIAP1 was shown to transcription-
ally regulate cyclin E [50], and we found that either 
NF45 or cIAP1 depletion caused a decrease in cyclin 
E expression that is rescued by NF45 re-expression. 
Coordinated changes in cyclin E and Survivin expres-
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sion in NF45-depleted cells would lead to a block 
in cell cycle, mitotic catastrophe and defects in cyto-
kinesis thus explaining the senescence-like phenotype 
of these cells. These observations uncover a novel role 
for NF45 in controlling ploidy and highlight the impor-
tance of IRES-mediated translation in the regulation 
of mitosis, cell growth and apoptosis. 
X-linked inhibitor of apoptosis protein (XIAP)
XIAP, a prototype member of the IAP family is a di-
rect inhibitor of caspases 3, 7, and 9. Given XIAP’s key 
role in inhibiting caspases, it is not surprising that 
misregulation of its expression is associated with tu-
mourigenesis and cancer. Importantly, elevated levels 
of XIAP, as is observed in many cancers, have been 
linked to enhanced chemo- or radiation resistance, 
whereas reduction of XIAP through chemical inhibitors 
can restore chemosensitivity [51].
Studies into the regulation of XIAP expression led 
to the discovery of an IRES element located in its 5’ 
UTR region which mediates XIAP protein translation 
under conditions of cellular stress such as γ-irradiation 
or nutrient deprivation, thus providing the cell with pro-
tection against apoptosis [53]. Interestingly, XIAP pro-
tein is encoded by two mRNA splice variants that differ 
only in their 5’UTR regions [53]. The more abundant, 
shorter transcript produces the majority of XIAP protein 
under normal growth conditions by cap-dependent 
translation. However, during cellular stress, the longer 
transcript that contains the IRES element supports ef-
ficient translation even though global cap-dependent 
translation is attenuated [54]. The secondary structure 
of the XIAP IRES and its associated ITAFs has been 
determined [55]. Some of these, such as La autoanti-
gen [55], hnRNP C1/C2 [56], and HuR [57] have been 
shown to enhance XIAP IRES translation, whereas oth-
ers, such as hnRNP A1 [58], PTB [54] and PDCD4 [59] 
repress XIAP IRES translation. 
Interestingly, cytoplasmic localization of XIAP ITAFs 
appears to play a key role in the regulation of XIAP 
translation in response to stress. For example, osmotic 
shock causes an accumulation of hnRNP A1 in the 
cytoplasm by activating the mitogen-activated protein 
kinase kinase 3/6-p38 signaling pathway resulting 
in phosphorylation of hnRNP A1, thus preventing its 
import into the nucleus [60]. Once in the cytoplasm, 
hnRNP A1 binds with the XIAP IRES and inhibits 
protein expression [58]. Another example of an ITAF 
being regulated at the level of localization was shown 
by Gu et al. [61] in acute lymphoblastic leukemia (ALL) 
cells treated with ionizing radiation (IR). They observed 
that IR treatment resulted in the misregulation of the 
oncogene MDM2. MDM2 overexpression is observed 
in many cancers and correlates with poor patient out-
come because it binds to and inhibits the activity of the 
tumour suppressor p53 [61]. It is known that the phos-
phorylation status of MDM2 dictates its localization 
such that survival signals promote nuclear localization 
and cell proliferation whereas cellular stress results 
in dephosphorylation of MDM2 and subsequent reten-
tion in the cytoplasm. However, the cytoplasmic func-
tion of MDM2 was not well understood. Upon treatment 
with IR, dephosphorylated MDM2 is retained in the 
cytoplasm and is no longer associated with its main 
target, p53 [61]. Instead, cytoplasmic MDM2 is able 
to directly and specifically bind to the XIAP IRES. It is in-
teresting to note that many cancers express elevated 
levels of a mutated form of MDM2 that does not contain 
the N-terminal p53 binding domain [62] and it is this 
remaining C-terminal portion of MDM2 that is respon-
sible for interacting with the XIAP IRES and upregulat-
ing its IRES-mediated translation. Importantly, the 
MDM2-mediated increase in XIAP expression leads 
to enhanced resistance to IR-induced apoptosis. 
Similar to DNA damage or osmotic shock, cell pro-
liferative stimulation also results in stimulation of IRES 
translation. For example, treatment of small cell lung 
cancer (SCLC) cells with the fibroblast growth factor 
(FGF) 2 protects them from etoposide induced cell 
death by upregulating the anti-apoptotic proteins XIAP 
and Bcl-xL. It was shown that a complex forms between 
S6 kinase 2 (S6K2), BRaf, and PKCε leading to acti-
vation of S6K2 in response to FGF 2 [63]. We have 
identified the target of activated S6K2 as programmed 
cell death 4 (PDCD4; [59]). PDCD4 is a known tu-
mour suppressor and its loss has been correlated 
with more aggressive and invasive tumours [64]. The 
FGF2-activated S6K2 phosphorylates PDCD4, lead-
ing to its proteasomal degradation. Furthermore, 
we identified XIAP and Bcl-xL as two novel translational 
targets of PDCD4. We showed that the N-terminal 
portion of PDCD4 was responsible for directly binding 
to XIAP and Bcl-xL IRES RNAs both in vitro and in vivo 
and the loss of PDCD4 correlated with an increase 
in XIAP and Bcl-xL protein expression. This response 
to FGF-2 is a critical factor in tumour formation and 
resistance to apoptosis because mutations in cancer 
cells typically lead to an acquired ability of the cells 
to produce growth factors and stimulate proliferation 
through autocrine signalling (reviewed in [65]). 
Tumour suppressor p53
p53 is a tumour suppressor that plays a major 
role in the regulation of cell cycle progression and 
apoptosis in response to cellular stress, mainly DNA 
damage and genomic instability [66]. p53 also plays 
a central role in the process of oncogenesis as its gene 
is mutated in more than 50% of all human cancers 
[67] and as such, p53 remains one of the most highly 
studied genes. It is now well established that p53 pro-
tein levels and activity increase in response to DNA 
damage and that regulation of this process occurs 
mainly at the level of protein stability by the ubiquitin 
ligase MDM2 [68]. However in recent years, there 
has been accumulating evidence that translational 
control is important in the induction of p53 expression 
in response to cellular stress (reviewed in [69]). This 
evidence includes, but is not limited to: (I) the fact 
that cycloheximide — a protein elongation inhibitor- 
prevents the increase in p53 protein levels normally 
observed after IR-induced [70] or etoposide-induced 
[71] DNA damage, (II) the fact that there is an increase 
Experimental Oncology 34, 218–230, 2012 (September) 225
in p53 mRNA in polyribosomes upon IR exposure [72] 
or etoposide treatment [71], and (III) the fact that 
de novo protein synthesis rates of the p53 mRNA in-
crease in response to DNA damage caused by IR [72, 
73], UVC [74], etoposide [71], doxorubicin or in re-
sponse to tunicamycin-induced ER stress [75].
In the past ten years, there has been more fo-
cus on understanding the mechanisms underlying 
p53 translation induction in response to cell stress. 
Yang et al. [71] were the first to report that the 
p53 mRNA can be translated in a cap-independent 
manner in MCF-7 breast cancer cells and subse-
quently identified an IRES within the p53 5’UTR that 
is induced more than 2-fold during etoposide-induced 
DNA damage. Moreover, a second study showed that 
the p53 5’UTR was able to direct in vitro translation 
of the p53 mRNA in the absence of a cap structure 
[76], further confirming the existence of a p53 IRES. 
Interestingly, Ray et al. [76] proposed a model 
in which two different IRES structures control the trans-
lation of two different p53 isoforms, namely the full-
length p53 protein (FL-p53) and the ΔN-p53 (p40/47) 
isoform. The ΔN-p53 protein is translated from 
an alternative initiation codon situated within the cod-
ing sequence, 40 nucleotides downstream of the FL-
p53 translation start site [77, 78]. It has been suggested 
that ΔN-p53 acts as a dominant-negative form that 
antagonizes p53-mediated transcription and growth 
regulation [77]. However it appears that ΔN-p53 func-
tions are much more complex since the protein does 
not contain an MDM2 binding site, is able to oligomerize 
with FL-p53 to induce different transcription patterns 
[78], and induces apoptosis when expressed in p53-null 
cells [77]. They further showed that expression of the 
two p53 isoforms is regulated in a cell-cycle dependent 
manner, via an IRES mechanism of translation [76]. 
In fact, the IRES driving FL-p53 protein expression 
is more active during the G2/M transition when p53 ac-
tivity is required the most, whereas the IRES driving ΔN-
p53 expression is active during the G1/S transition [76]. 
These findings are more consistent with ΔN-p53 being 
an antagonist of p53 activity where at the G1/S phase 
it would drive the expression of genes necessary for 
transition through the cell cycle. Differential regulation 
of FL-p53 and ΔN-p53 via translational control may 
also have an effect on cell sensitivity to apoptosis. 
For instance, doxorubicin-induced DNA damage and 
tunicamycin-induced ER stress give rise to different 
patterns of p53 isoform expression where H1299 lung 
carcinoma cells overexpressing the ΔN-p53 are less 
sensitive to doxorubicin treatment and more sensitive 
to tunicamycin [75]. Thus, translational control via the 
IRES is an important mechanism by which p53 can 
integrate and respond to the different apoptotic or pro-
liferative cues the cell is exposed to. Another layer 
of complexity is brought about by the different ITAFs that 
can bind to the p53 IRES and modulate its activity in re-
sponse to stress. The ribosomal protein L26 [73], PTB 
[79], and hnRNP C1/C2 [80] were all shown to enhance 
p53 expression, whereas nucleolin was shown to re-
press it [73]. The La autoantigen, hnRNP U and p53 itself 
may also be potential p53 IRES trans-acting factors 
[73]. PTB binds specifically to the p53 IRES structure 
and a reduction in PTB protein levels by RNA interfer-
ence leads to a decrease in IRES activity and blunting 
of p53 isoforms induction in the presence of doxorubi-
cin [79]]. Furthermore, treatment of A549 human lung 
carcinoma cells with doxorubicin causes PTB transloca-
tion from the nucleus to the cytoplasm, corresponding 
with an increase in p53 expression. Interestingly PTB 
cytoplasmic levels are high at the G2/M phase and low 
at the G1/M transition [81], suggesting that PTB might 
be the factor contributing to increased p53 translation 
during the G2/M checkpoint [79]. These results further 
support the notion that cell stressors can alter the ex-
pression level, cellular localization or status of different 
ITAFs to modulate the output of p53 protein available 
to respond to the stress and decide the fate of the cell. 
Most of the work done on p53 in the context of car-
cinogenesis was aimed at characterizing the effects 
of p53 coding region mutations on the transcriptional 
activities of the protein. However, it has become appar-
ent that mutations can also occur within the p53 5’UTR 
and may have relevance to the pathology of cancer 
[82]. Indeed, a cancer-derived triple silent mutation 
at positions 185, 188 and 191 that was previously 
shown to alter MDM2 binding to the p53 mRNA [82], 
as well as a single silent mutation at position 200 of the 
p53 5’UTR [82] were found to alter p53 IRES activity, 
alter the profile of ITAFs binding to the IRES and blunt 
the IRES induction in response to doxorubicin [83]. 
Thus, it is possible that mutations within the p53 IRES 
may lead to carcinogenesis by decreasing p53 induction 
and protective activity in response to DNA damage. The 
recent characterization of the p53 IRES structure [83] 
may help in identifying more cancer-derived mutations 
that are relevant to p53 function and that could be used 
as predictors of response to treatments. 
Another aspect that may be relevant to the pathology 
of cancer was the recent finding that p53 IRES-dependent 
translation is impaired during oncogene-induced senes-
cence (OIS) in DKC1m cells [84]. The DKC1 gene encodes 
the dyskerin protein which is responsible for modifying 
uridines in ribosomal RNA into pseudouridines, and 
mutations in DKC1 have been linked to the development 
of X-linked dyskeratosis congenita (X-DC). X-DC patients 
have increased susceptibility to cancer, as reflected by the 
fact that more than 50% of DKC1m mice develop tumours 
of different origin [85]. Interestingly, Yoon et al. [86] showed 
that DKC1-mutated cells are impaired in IRES-mediated 
translation, providing one of the first in vivo links between 
IRES-mediated translation and the onset of oncogenesis. 
In addition, during OIS, in which p53 translation is normally 
induced to counteract the oncogenic insult [87], p53 IRES-
mediated translation is impaired both in DKC1m mice cells 
and in X-DC patient derived cells. This results in a signifi-
cant decrease in p53 protein induction and of its target 
genes p21 and MDM2 in response to etoposide treatment 
or γ-irradiation which correlates with a reduction in the 
number of apoptotic cells as compared to wild-type [84]. 
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These results were corroborated by an independent group 
that showed that DKC1 knock-down in both MCF-7 breast 
cancer cells and in primary breast cancer cells caused 
a decrease in p53 IRES-mediated translation, which led 
to a decrease in p53 transcriptional activity and apoptosis 
upon doxorubicin treatment [88]. Together, these findings 
show that defects in p53 IRES-mediated translation are 
relevant not only to the OIS process but also to carcino-
genesis, particularly in the context of the X-DC pathology. 
MICRORNA MEDIATED REGULATION
MicroRNAs (miRNAs) are small, non-coding RNA 
sequences of approximately 21 nucleotides in length 
that regulate gene expression post-transcriptionally 
by binding to target mRNAs to silence their expres-
sion. miRNAs play a significant role in regulating 
processes as diverse as development, metabolism, 
cell proliferation, and apoptosis [89]. In humans, over 
500 miRNAs have been identified so far and each 
miRNA has multiple targets, therefore it is thought that 
about 10,000 mRNAs could be regulated by miRNAs. 
miRNAs are transcribed from the genome by RNA 
polymerase II or III as long, double-stranded hairpin 
transcripts containing a 5’cap and 3’ poly-A tail, termed 
primary miRNA (pri-miRNA [90]). Pri-miRNAs are further 
processed into a smaller double stranded structure 
in the nucleus by the RNase III-like enzyme Drosha and 
DGCR8 to produce the precursor miRNAs (pre-miRNAs) 
[91] that are subsequently are exported into the cyto-
plasm by exportin-5 where they are further processed 
by the RNase III enzyme Dicer, yielding an approximately 
22 nucleotide long, double-stranded product [92]. Only 
one of the miRNA strands is then incorporated into the 
RNA-induced silencing complex (RISC) containing 
the argonaute (AGO) protein, while the other strand 
is degraded [90, 93]. Upon recognition of their target 
mRNAs via near-perfect complementarity, miRNAs can 
direct the degradation of the target mRNA by the 5’-to-
3’ mRNA decay pathway which involves deadenylation 
by the CAF1-CCR4-NOT deadenylase complex, followed 
by decapping by DCP2, and ultimately degradation by the 
exonuclease XRN1 [94, 95]. As well, miRNAs that bind 
with near perfect complementarity can direct endonu-
cleolytic cleavage of their target mRNAs through the 
catalytically active Argonaute protein present in the RISC 
complex [96]. On the other hand, miRNAs can also bind 
their target mRNAs via imperfect complementarity result-
ing in a loss of protein product but no change in mRNA 
levels suggesting that an inhibition of translation occurs 
rather than degradation of mRNA. Early studies showed 
that these inhibited mRNAs were found associated with 
polysomes indicating that repression occurred at a post-
initiation stage, likely during translation elongation [97, 
98]. However, in recent years, it has been suggested that 
miRNAs inhibit translation initiation by interfering with 
the eIF4F and the poly-A binding complexes. Further 
evidence for miRNAs affecting the initiation step of trans-
lation was provided by Humphreys et al. [99] who showed 
that a construct containing the IRES element of cricket 
paralysis virus (CrPV) lacking a cap and poly-A structure 
was unaffected by miRNAs, suggesting that the initiation 
step was the target of miRNA regulation, since regula-
tion of elongation or termination should still occur in the 
presence of the CrPV IRES. These data strengthen the 
link between miRNA function and translational control 
which is important not only during times of cellular stress, 
but also during the cell’s decision to undergo apoptosis. 
As mentioned above, many mRNAs that are involved 
in the cellular stress response contain IRES elements, 
which not only allow the mRNA to be translated during at-
tenuation of cap-dependent translation, but may also aid 
in protecting the mRNA from miRNA induced silencing. 
Furthermore, cytoplasmic processing bodies (P-bodies), 
which are involved in processes such as translation in-
hibition and mRNA degradation, have been suggested 
to be involved in retaining repressed mRNAs in the RISC 
complex thus preventing translation [100–102]. Inter-
estingly, certain stressors can cause release of some 
repressed mRNAs from the P-bodies where they are able 
to re-enter into polysomes for efficient translation [103]. 
For example, in Huh7 hepatoma cells, the cationic amino 
acid transporter (CAT-1) mRNA is found in the P-bodies. 
However, upon exposure to amino acid starvation, the 
RNA binding protein HuR is relocalized from the nucleus 
to the cytoplasm where it binds the CAT-1 mRNA and 
releases it from the P-bodies. This allows translation 
of the mRNA to respond to the cellular stress. It is likely 
that this mechanism of release under stress occurs 
for other mRNAs in response to specific stressors and 
the combination of these mechanisms allows the cell 
to quickly respond to its changing environment by trans-
lating pro- or anti-apoptotic proteins that are crucial for 
deciding the fate of the cell.
Interestingly, miRNAs have been identified as both 
tumour suppressors and oncogenes involved in tumour 
development, and mis-regulation of miRNA expression 
has been linked to cellular transformation. It has been 
suggested that as many as 50% of miRNAs are located 
in unstable regions of chromosomes that are prone 
to being amplified or deleted in many cancers [104]. 
Furthermore, proteins that are frequently mis-regulated 
or mutated in cancers can affect the levels of miRNAs. 
For example, upon DNA damage, p53 interacts with the 
Drosha complex to enhance the processing of select pri-
miRNAs involved in apoptosis and cell proliferation [105]. 
However, inactive p53 mutants that are commonly found 
in many cancers (for example p53 mutated at C135Y, 
R175H and R273H) prevent the interaction of p53 with the 
Drosha complex, therefore attenuating the processing 
of these miRNAs. Many miRNAs have been implicated 
in regulating expression of apoptotic proteins, thus al-
tered levels of these miRNAs can have negative effects 
on the cells ability to respond to apoptotic cues, result-
ing in a lack of cell death and enhanced proliferation, 
ultimately leading to tumour growth and survival. (For 
a detailed review on miRNAs see [106, 107]).
miRNA 21 is the most consistently up-regulated 
miRNA across many cancer types. Chan et al. [108] 
discovered that reducing miR-21 levels in glioblas-
toma cells increased apoptosis, which correlated with 
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a decrease in tumour growth. Of the many targets 
of miR21 [109], PDCD4 is an important target that 
is frequently down-regulated in a variety of cancers [110, 
111]. The tumour suppressive function of PDCD4 stems 
from its ability to bind to and inhibit eIF4A, thus blocking 
cap-dependent translation and attenuating cell growth 
[112–114]. Upon loss of PDCD4, the cell loses this ability 
to regulate protein translation, leading to enhanced cell 
proliferation and increased tumour formation. However, 
we and others have shown recently that PDCD4 plays 
a more specific role in translation by regulating transla-
tion of a specific set of targets (as described above; [59, 
115]. For example, PDCD4 can bind to and negatively 
regulate the expression of p53 under normal growth 
conditions. However, upon induction of DNA damage 
by ultraviolet irradiation (UV), PDCD4 is degraded, 
thus allowing for an up-regulation in p53 levels [116]. 
Similarly, PDCD4-dependent repression of XIAP and 
Bcl-xL in response to FGF 2 has been described above. 
This suggest that an increase in miR-21 leading to a loss 
in PDCD4 may not only result in an increase in overall 
translation through de-repression of eIF4A, but also 
to a specific increase in expression of anti-apoptotic 
proteins, thus leading to enhanced resistance to apop-
tosis-inducing chemotherapeutics [59].
The Bcl-2 family of proteins has also been identified 
as being regulated directly by miRNAs. For example, 
the miR-15-16 cluster of miRNAs can induce apoptosis 
by inhibiting Bcl-2, an anti-apoptotic factor involved 
in maintaining mitochondrial membrane homeostasis. 
As is common for many miRNAs, this cluster is down 
regulated in many cancers. For example, the miR-
15–16 cluster is deleted in B-cell chronic lymphocytic 
leukaemia (CLL; [117]), pituitary adenoma [118], and 
prostate carcinoma [119]. This down-regulation of miR-
NAs contributes to the increased expression of Bcl-2 that 
is often observed in many cancers, and promotes che-
moresistance by inhibiting the release of mitochondrial 
cytochrome c required for activation of caspase 9. 
Interestingly, apoptotic cues can also directly regu-
late the proteins involved in the miRNA process. For 
example, Matskevich et al. [120] demonstrated that 
the RNase III enzyme Dicer is cleaved by caspases 
in response to apoptotic cues, in particular inhibition 
of protein kinase C (PKC) as well as during HIV infec-
tion, resulting in an inhibition of the RNA interference 
pathway [120]. Furthermore, Nakagawa et al. [121] 
demonstrated that the C. elegans Dicer gene, DCR-
1, is cleaved specifically by a caspase, CED-3. They 
identified a novel role for the remaining C-terminal 
fragment of Dicer that can no longer process double 
stranded RNA species, but instead gains a deoxyri-
bonuclease activity that can nick DNA leading to DNA 
degradation and enhanced apoptosis [121].
As mentioned above, many miRNAs play a large 
role in regulating genes involved in apoptosis or cell 
proliferation leading to development and progres-
sion of cancer. Recently, miRNA profiles have been 
generated that can be utilized as a tool for the identi-
fication and classification of tumours with hopes that 
this information can help with disease prognosis and 
predictions of outcomes [122]. 
CONCLUSIONS
Regulation of translation can be both the cause 
and the consequence of apoptosis. We have chosen 
examples to illustrate how this process is highly dy-
namic and is crucial for the cell’s ability to respond 
to environmental cues (Fig. 2). We have highlighted the 
critical points of control prior to and during the onset 
of apoptosis with the hope of convincing the reader 
that the ability to translate specific proteins in response 
to stress is essential to decide the fate of the cell. Both 
the IRES and miRNA-mediated control of translation 
initiation are emerging as key mechanisms that regulate 
selective translation. IRES mediated translation allows 
for a selective translation of a subset of mRNAs in times 
of attenuation of global cap-dependent translation 
by bypassing the requirement for canonical initiation 
factors that are subject to inhibitory modifications dur-
ing apoptosis. In contrast, miRNA-mediated control 
of translation may, in addition to regulating the expres-
sion of specific target mRNAs, protect IRES containing 
mRNAs from degradation. These examples demon-
strate how misregulation of translation initiation plays 
a crucial part in tumorigenesis and chemoresistance 
through enhanced resistance to apoptosis. 
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